Skip to main content
. 2019 Sep 11;30(12):2307–2320. doi: 10.1681/ASN.2019010053

Figure 3.

Figure 3.

Loss of podocyte specific Angiotensin II type 1a receptor (Agtr1a) on the Dnm DKO mouse background improves albuminuria and renal function. (A) Agtr1a Neo, Agtr1a flox, Dnm1, Dnm2, and Podocin-Cre genotypes confirmed by tail genotyping. (B) Agtr1a mRNA expression in control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO (blue) mouse primary podocytes by RT–PCR. *P<0.05. n=3. (C) Body weight at 2, 4, and 6 weeks of age in control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO (blue) mice. *P<0.05. n=5. (D) Survival curves of control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO mice (blue). n=5. (E) Urine albumin normalized to urine creatinine at 2, 4, and 6 weeks of age in control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO (blue) mice. *P<0.05. n=5. (F) Plasma creatinine levels at 4 weeks of age in control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO (blue) mice. *P<0.05. n=5. (G and H) Mean arterial BP (G) and heart rate (H) measured by tail cuff at 4 weeks of age in control (black), Dnm DKO (red), and Agtr1afl/− Dnm DKO (blue) mice. n=10. BW, body weight; Ctrl, control.